69 - Merck

An employee monitors Euthyrox hypothyroid treatment tablets as they pass through a blister pack packaging machine inside Merck KGaA's pharmaceutical laboratories at the company's headquarters in Darmstadt, Germany, on Thursday, Nov. 3, 2016. Merck and Idemitsu Kosan Co Ltd. today signed an agreement to allow each party to use the other's organic light-emitting diode (OLED) material-related patents in certain areas. Photographer: Martin Leissl/Bloomberg via Getty Images Martin Leissl — Bloomberg via Getty Images

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Read more!

Key Metrics & Financials (Last Fiscal Year)

Revenues ($M)$39807
Revenue Percent Change0.8%
Profits ($M)$3,920.0
Profits Percent Change-11.8%
Assets ($M)$95377
Market Value — as of March 31, 2017 ($M)$174,454
Previous Rank72

Company Facts

SectorHealth Care
HQ LocationKenilworth, NJ
CEOKenneth C. Frazier
CEO Title-
Years on Fortune 500 List23

See Full List

Read more!